Clinical Trial Update: Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology [Phase 3]

View source ↗

Summary

Phase III trial evaluating Florbetaben PET imaging for detecting cerebral beta-amyloid compared with histopathology has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• florbetaben (florbetaben)

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-25